Falling US flu vaccine rates hurt Australia's CSL profit growth
The Behring unit, which makes up around 70% of CSL's revenue, recorded a 15% jump in immunoglobulin sales to $3.17 billion, ...
Motley Fool Australia4d
CSL share price on watch amid $2.1b half year profit and dividend hike
Finally, CSL Vifor sales were up 6% to US$1.08 billion for the six months. This was driven by continued volume growth for iron products in Europe, despite generic competition, and strong Tavneos ...
pharmaphorum3d
CSL, Travere close on EU approval of IgAN drug sparsentan
Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...
pharmaphorum5d
Vifor forges iron drug partnership with Fresenius in China
The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China.
The Australian Financial Review2d
CSL Limited
Research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines.
inkbotdesign.com2d
Top 20 Fashion Logos: Best Designs in the Industry
Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...